Company news

Entropy Neurodynamics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Binge Eating Disorder Trial receives Human Ethics approval

June 22, 2025

TRP-8803 BED trial to commence with Swinburne this quarter

April 9, 2025

Appendix 4D and Half Year Report for period 31 Dec 2024

February 26, 2025

Positive interim results in Phase 2a TRP-8802 IBS trial

December 17, 2024

Phase 1b extension results meet study objectives

December 15, 2024

Phase 1b determines optimal parameters for TRP-8803 use

November 18, 2024

$6m funding to fast track TRP-8803 clinical trial strategy

October 29, 2024

Pause in Trading

October 27, 2024

TRP-8803 doses deemed safe by SRC following phase 1b study

October 17, 2024

Preliminary Final Report Reporting Adjustments

September 30, 2024

Appendix 4E Preliminary Final Report

August 29, 2024

Completion of patient dosing in maiden TRP-8803 trial

August 25, 2024

Positive Phase 2a fibromyalgia results across all patients

August 11, 2024

Maiden dosing of TRP-8803 completed in global first

July 1, 2024

Reinstatement to Quotation

May 28, 2024

Results of 2024 General Meeting

April 11, 2024

Disclosure Document - Replacement Prospectus

March 28, 2024

Disclosure Document - Prospectus

March 14, 2024

2024 General Meeting Letter of Access, Notice and Proxy

March 12, 2024

EX1 signs binding agreement to acquire Tryp Therapeutics

March 8, 2024

Appendix 4D and Half Year Report for period 31 December 2023

February 26, 2024

Further management changes and cost-reductions

November 27, 2023

Suspension from Quotation

October 2, 2023

FY2023 Appendix 4E

August 28, 2023

EX1 early stage success with in house Elastin (ELN) program

April 27, 2023

Results of Non-Renounceable Rights Issue

April 25, 2023

Exopharm Limited announces Non-Renounceable Pro Rata Rights

March 22, 2023

Disclosure Document - Rights Issue Prospectus

March 22, 2023

EX1 to Receive $1m from the Issue of Convertible Notes

March 9, 2023

EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive

March 8, 2023

Appendix 4D and Half Year Report for period 31 December 2022

February 26, 2023

Added Funding for 2023

February 12, 2023

EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive

November 25, 2022

Exopharm Received R&D Tax Incentive Refund

October 26, 2022

Study results indicate exosomes safe for clinical pursuit

September 27, 2022

FY2022 Appendix 4E and Annual Report

August 30, 2022

EX1 to receive a further $0.48m in prepaid R&D Tax Incentive

July 28, 2022

EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim

June 16, 2022

Business Update

May 29, 2022

Response to ASX Price Query

April 27, 2022

Appendix 4D and Half Year Report for period 31 December 2021

February 25, 2022

Response to ASX Query

February 3, 2022

Exopharm and AIRM Sign MSA

January 30, 2022

Exopharm Gains US Patent for LEAP Technology

December 21, 2021

Exopharm LEAP Technology - Further Step Towards US Patent

September 26, 2021

Exopharm LEAP Technology - Second Commercial Collaboration

September 8, 2021

FY2021 Appendix 4E and Annual Report

August 29, 2021

Exopharm LEAP Exosome Technology Granted 1st National Patent

June 3, 2021

Exopharm Receives Firm Commitments to Raise $12 million

April 19, 2021

Positive PLEXOVAL II Phase 1 Clinical Trial Results

April 5, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.